Teprotumumab (Anti-IGF-1R / CD221)
Teprotumumab is a fully human monoclonal antibody designed to target the insulin-like growth factor-1 receptor (IGF-1R), also known as CD221. By binding to IGF-1R, teprotumumab inhibits receptor signaling and has been studied for its effects on biological pathways associated with IGF-1R activity.
Teprotumumab is best known as the active ingredient in Tepezza, an FDA-approved prescription medicine for the treatment of Thyroid Eye Disease (TED). It is administered by intravenous infusion under the supervision of qualified healthcare professionals.
Product Information
- Name: Teprotumumab
- Target: IGF-1R / CD221
- Type: Fully human monoclonal antibody
- Format: Lyophilized powder for intravenous infusion
- Research area: IGF-1R signaling and Thyroid Eye Disease
- Intended use: Prescription medical use / regulated research applications
Important Information
Teprotumumab is a prescription biologic medicine, not an ordinary laboratory supplement. Its use requires appropriate medical oversight. Consult the current official prescribing information and a qualified healthcare professional for indications, dosing, contraindications, warnings, and administration requirements.
Teprotumumab (Anti-IGF-1R / CD221) is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab can be used for thyroid-associated ophthalmopathy research.MW: 145.5 KD.
Reviews
There are no reviews yet.